Dr. Ostacher is Associate Professor of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, and at the VA Palo Alto Health Care System, where he is the Associate Director of the Bipolar and Depression Research Program and the Director of Advanced Fellowship Training in Psychiatry. He is a Digital Content Editor for Evidence-Based Mental Health and is a member of the editorial boards of Bipolar Disorders, the International Journal of Bipolar Disorders, and the Journal of Clinical Psychiatry. He is the Co-Chair of the Bipolar Disorder Task Group of the National Network of Depression Centers. He was the principal investigator at Harvard for BALANCE, a multinational study of maintenance treatments for bipolar disorder at University of Oxford, was the Site PI for the NIMH Bipolar Trials Network while at MGH, and is an investigator for a VA-wide multicenter study of lithium for suicide prevention in bipolar disorder in the US. His primary research interest is in large clinical trials in bipolar disorder and the implementation of evidence-based mental health practices.
Michael Ostacher provides a robust appraisal of a recent UK cohort study that suggests bipolar disorder patients taking lithium had reduced self-harm and unintentional injury rates, when compared with patients taking valproate, olanzapine or quetiapine.[read the full story...]
Michael Ostacher considers the findings of the CEQUEL trial, which asks: Does lamotrigine treat bipolar depression when added to quetiapine, and does adding folic acid help any more?[read the full story...]
Michael Ostacher provides some context and ideas for the JoinMQ conference on research priorities for bipolar disorder, which is taking place in London on 9-10 November 2015.[read the full story...]